Archive | September, 2016

Heading to JPM? Read The RESI SF Agenda

29 Sep

By Dennis Ford, Founder & CEO, LSN


Biotech and medtech industry executives are already drawing up their itineraries for January’s healthcare conference week in San Francisco. It’s on track to be a busy week for us all. Among the many events and receptions taking place, the Redefining Early Stage Investments Conference (RESI SF) stands alone in providing a targeted opportunity for early stage biotech and medtech companies to schedule up to 16 face-to-face investor meetings in one venue, with the potential for many more ad-hoc investor discussions throughout the day.

Partnering is RESI’s core, but at RESI SF also provides a full day of investor panels and workshops devoted to early stage life science investment topics. We’ll see the return of the RESI Asia-North America track, with content for entrepreneurs who are looking to the Asia Pacific region as a source of investment or future customers. RESI will also feature sessions focused on investors in each main life science technology vertical, and on key investor categories including Family Offices, Angels and Big Pharma, and a new session on Tech Giants in Healthcare.

With a full day of content and meetings, we’re on course for another sellout San Francisco RESI event. Don’t leave it too late to get your ticket.



Life Science Investor Landscape: Who’s Out There, and What Are They Looking For?

29 Sep

By Lucy Parkinson, Director of Research, LSN

LSN’s research staff continue to inverview life science investors from all over the world and collect in depth information on each investor’s unique parameters and focus areas. In this article, we’ll take a quick overview of the current landscape.  All these charts are based on a sample of investors that have been interviewed by LSN Research in 2016.

Firstly, what type of investors are currently looking into life science and health innovation deals?  While venture capital and private equity remain a significant source of startup funds, we also speak with many major corporations in healthcare and their corporate VC arms, in addition to private and family office investors, angels, foundations, and others. A successful fundraise may involve speaking with investors from all of these groups.

LSN focuses on four main verticals within health innovation; therapeutics, medical devices, diagnostics and healthcare IT. Many firms invest in more than one of these sectors; others have a specific lens on only one sector. Among the investors LSN has spoken with recently, medical technology and diagnostics are the most popular sectors. These products can attract interest both from traditional life science investors and from newer players in the sector, including major technology firms that are increasingly taking an interest in healthcare innovation.


Many investors are particular about what stage of development a lead asset must have reached before they’re willing to make an investment.  LSN finds that most often, the biotech investors we speak to are looking for preclinical-stage or Phase I assets, with many also open to considering assets at Phase II or later. Given the need for funding at these crucial early stages of product development, our bias is to uncover investors that are willing to stake their money at or soon after the IND.

In medtech and diagnostics, it’s a somewhat different story due to the much compressed development timeline of these products as compared with therapeutics. We find the greatest amount of interest in devices and diagnostic tests that are in clinical trials. While there are many investors out there that will make medtech investments prior to entering the clinic, slightly more are interested in marketed products that need capital for commercialization and growth.


Where are these investors looking for deals?  About a third of those we speak with are open to life science opportunities anywhere in the world. Others are focused on one or more regions; the major life science investment regions are shown below.


If you’re looking for capital and need to prepare for a fundraising roadshow, LSN’s curated information on what investors want to see and how to contact them could help you to map out your campaign. If you’d like to take a closer look at the investors that are looking for new technologies in your sector, you can reach out to for a demo.

LSN Summer Reading Series, Chapter 14: “Thirty-One Tips for Effective Fundraising”

29 Sep

By Nono Hu, Director of Marketing, LSN

To bring LSN’s Life Science Executive’s Fundraising Manifesto toward a close, we provide some motivational advice and tactical reminders to help a fundraising CEO bring their outbound campaign to a successful resolution.

With illustrations and helpful mottos, this ‘cheat sheet’ chapter will help the reader find their way through the fundraising maze in good spirits. From how to stay optimistic during the tough times, to when to stop marketing to investors, this chapter has it covered.

Click here to download/print the chapter PDF

Join us next week for the book’s addendum: “The View Beyond Venture Capital.”

Enjoyed the preview? Buy now from or Barnes & Noble


Hot Investor Mandate 1: $100 Million Fund Makes Early Stage Deals in Therapeutics, Devices and Diagnostics

29 Sep

An investment firm based in Taiwan is interested in the life sciences and will target new investments from a new USD 100 million fund. The firm can sometimes leverage different funds to invest. The fund’s target investment size is USD 3-5 million per company and USD 1-1.5 million for early stage companies. Capital allocation per company will not exceed 10% of the fund. The firm seeks companies in Asia-Pacific, including the US and Japan. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is interested in therapeutics, medical devices, and diagnostics. For therapeutics, the firm will consider a broad range of modalities including small molecules and biologics with an emphasis on stem cell, immunotherapy, and CNS therapies. The firm is opportunistic in terms of indications. For companies in Asia, the firm is agnostic to the phase of development. For overseas deals, the firm is currently looking for preclinical to phase 2 assets. The firm prefers candidates with in-human data and are conducting clinical trials in the US, while this is not a requirement.

For devices, the firm considers minimally invasive class III devices in the cardiovascular and cancer space that have prototype and have obtained proof-of concept. For diagnostics, the firm is interested in genomics and big data analytics. Recently there is an interest in the cosmetics and supplements area, and the firm is seeking acquisition opportunities to commercialize products through distribution channels within its network.

The firm only invests in private companies and aims to be a minority investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 2: Corporate VC Seeks Digital Medicine Devices and Wearables in Chronic Care

29 Sep

A pharma firm established a new corporate venture arm in 2015.  The firm is based in London and invests from a $30M fund, typically contributing $250K-$3M to a finacing round. The firm will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally, but focus on US-based investments.

Within digital health, the firm is seeking digital medicine devices and wearables that address chronic or respiratory diseases, oncology, and consumer health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with full management teams with a track record in the space. A strong business plan should be in place, and companies should have IP around their products.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 3: Asia-based Firm Invests in US Therapeutics and Devices at Series A and B

29 Sep

An Asia-based investment firm backed by a large bank is managing a US$60M healthcare fund raised in 2014.  The firm invests in several sectors across healthcare. The firm generally participates in Series A or B rounds and prefers a clear exit in less than 5 years. The firm is open to both leading and co-investing. Typical equity investments range from US$2-10M. The firm currently focuses 60% on regional-based deals and 40% on China- and US-based deals.

The firm considers therapeutics and medical devices. Within therapeutics, the firm is open to all modalities including small molecules, biologics, cell therapy and gene therapy with a focus on cancer therapies. The firm would also consider R&D services, healthcare services, and healthcare IT products such as EMR management software. The firm seeks to invest in venture stage companies in Series A or B rounds.

The firm prefers to back entrepreneurs with a successful track record. The firm typically requests a board seat in their portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 4: Korea Fund Opens US Office To Invest In Oncology, Opthalmology & Platform Technologies

29 Sep

An investment firm headquartered in Seoul, Korea, has established a US office in Boston to focus on US-based biotechnology companies. The firm invests from their third fund of $500 million. The firm is interested in opportunities at all stages of development and can allocate from $500 K up to $20 M in equity investments, acting as a lead or follow on.

The firm is currently focusing on the areas of immuno-oncology, gene therapy, ophthalmology, and platform technologies. Recent investments include companies targeting clinical stage small molecule therapeutics for oncology, peptide drugs for inflammatory diseases, and delivery methods and therapeutics in ophthamlology.

The story behind the company and management team is important to this firm. They look for a cohesive business plan and strategy, and are especially interested in opportunities with potential to expand into the Korean market.

If you are interested in more information about this investor and other investors tracked by LSN, please email